Aveo ISIN: US0535883070 Forum: Aktien User: Gambler10101

Offizielle Aveo Pharma Seite

Link bitte

Haben die Zulassung bekommen.Jetzt müsste so langsam was passieren. Denke es wird die nächsten Tage was gehen..

Das wird

AVEO Oncology Reports First Quarter 2021 Financial Results and Provides Business Update https://finance.yahoo.com/news/aveo-oncology-reports-first-quarter-200500853.html – U.S. Commercial Launch Underway with Fully Deployed Sales Force Following FDA Approval of FOTIVDA® (tivozanib) on March 10, 2021 – – FOTIVDA Net Product Revenue of $1.1 Million from Initial Distributor Orders in the Last Week of Q1; All Distributors Have Placed Reorders for Q2 – – Entered Clinical Trial Collaboration and Supply Agreement with Bristol Myers Squibb for Planned Pivotal Phase 3 TiNivo-2 Study of FOTIVDA in Combination with OPDIVO® (nivolumab); Study Anticipated to Commence Mid-2021 – – Phase 2 Open Label Randomized Study Results of Ficlatuzumab in HNSCC to be Presented at ASCO; Phase 3 Decision Anticipated Mid-2021 – ...

AVEO Oncology to Announce First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 10, 2021 https://www.businesswire.com/news/home/20210503005222/en/AVEO-Oncology-to-Announce-First-Quarter-2021-Financial-Results-and-Host-Conference-Call-and-Webcast-on-May-10-2021

AVEO Pharma US Patent & Trademark Office Abstract For Co.'s 'ANTI-GDF-15 ANTIBODIES' https://www.benzinga.com/news/21/04/20541474/aveo-pharma-us-patent-trademark-office-abstract-for-co-s-anti-gdf-15-antibodies ...The disclosed antibodies prevent or inhibit the activity of (i.e., neutralize) hGDF15. When administered to a mammal, the antibodies can inhibit the loss of muscle mass, for example, the loss of muscle mass associated with an underlying disease. The underlying disease may be selected from the group consisting of cancer, chronic heart failure, chronic kidney disease, COPD, AIDS, multiple sclerosis, rheumatoid arthritis, sepsis, and tuberculosis. In some embodiments, the loss of muscle mass may be accompanied by a loss of fat mass. The disclosed antibodies can also be used to inhibit involuntary weight loss in a mammal. In some embodiments, the disclosed antibodies may also be used to inhibit the loss of organ mass. Further, a method of treating cachexia and/or sarcopenia in a mammal comprising administering an effective amount of one of at least one of the disclosed antibodies to a mammal in need thereof is disclosed.

Lass sie doch! Kommt wiedee

Wie immer runter

Save

Die geht runter auf 5 Euro in den nächsten Tagen

Rockyciano meinst du wirklich? 😊😃

Och Charly! Wird schon

Jeden Tag nur Minus

Die Aktie ist so ein Witz hätte sie als sie über 10 € stand verkaufen sollen

https://finance.yahoo.com/news/aveo-oncology-announces-addition-fotivda-110000927.html